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A B S T R A C T
Outbreaks of human epidemic nonbacterial gastroenteritis are mainly caused by noroviruses. Viral replication
requires a 3C-like cysteine protease (3CLpro) which processes the 200 kDa viral polyprotein into six functional
proteins. The 3CLpro has attracted much interest due to its potential as a target for antiviral drugs. A system for
growing high-quality crystals of native Southampton norovirus 3CLpro (SV3CP) has been established, allowing
the ligand-free crystal structure to be determined to 1.3 Å in a tetrameric state. This also allowed crystal-based
fragment screening to be performed with various compound libraries, ultimately to guide drug discovery for
SV3CP. A total of 19 fragments were found to bind to the protease out of the 844 which were screened. Two of
the hits were located at the active site of SV3CP and showed good inhibitory activity in kinetic assays. Another 5
were found at the enzyme’s putative RNA-binding site and a further 11 were located in the symmetric central
cavity of the tetramer.
1. Introduction
Gastroenteritis accounts for the deaths of over 2000 children every
day worldwide, making it the second leading cause of death for children
under the age of 5, more than the combination of AIDS, malaria and
measles (Liu et al., 2012). Whilst there are many other causes of gas-
troenteritis, including parasites, bacteria and viruses, human calici-
viruses are recognised as the leading cause of gastroenteritis worldwide
among people of all ages. The Caliciviridae family contains five genera
known as norovirus, vesivirus, nebovirus, sapovirus and lagovirus
(Clarke et al., 2012) with norovirus being the most common cause of
disease in humans (Lambden et al., 1993).
Noroviruses account for more than 50% of gastroenteritis cases and
at least 90% of nonbacterial acute gastroenteritis cases worldwide, as
reported by the Centers for Disease Control and Prevention in the US
(2011). Scallan et al. (2011) estimated that 99% of all viral foodborne
illness incidents are caused by noroviruses which corresponds to 5.5
million per year in the US alone. From 2009 to 2013, around 62.5% of
norovirus cases needed long-term care facilities in order to control the
transmission (Vega et al., 2014). Statistics are generally similar in
Europe (Baert et al., 2009; Phillips et al., 2010). Globally, it is estimated
that noroviruses lead to a total of $4.2 billion in direct health system
costs and $60.3 billion in social cost per year (Bartsch et al., 2016).
Clinical treatment and intervention is hampered by the lack of li-
censed vaccines or antivirals. Treatment with human immunoglobulin
did show some benefit but did not result in clearance of the virus
(Florescu et al., 2008). Whilst development of a vaccine has been hin-
dered by the lack of small-animal models and cell culture systems, a
number of norovirus vaccines are yielding promising results in clinical
trials (e.g. Bernstein et al., 2015; Mateo et al., 2020). In general, nor-
ovirus vaccines are based on the use of virus-like particles formed by
the main capsid protein VP1 (Lucero et al., 2018). A recent review of
the development of norovirus antiviral agents and their targets is given
by Netzler et al. (2019).
Noroviruses are genetically classified into 7 genogroups, GI - GVII,
based on the amino acid sequence of the VP1 capsid protein and are
https://doi.org/10.1016/j.yjsbx.2020.100031
Received 30 March 2020; Received in revised form 15 June 2020; Accepted 7 July 2020
⁎ Corresponding author.
E-mail address: jon.cooper@ucl.ac.uk (J.B. Cooper).
1 Present address: The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, CB2 0QQ, UK.
Journal of Structural Biology: X 4 (2020) 100031
Available online 16 July 2020
2590-1524/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
further segregated into at least 40 genotypes (Vinjé, 2015). Noroviruses
from groups GI (like Southampton virus) and GII infect humans, as do
members of the GIV.1 subgroup. GII viruses are the most frequently
detected (89%) while GII.4 are the major cause of norovirus outbreaks
worldwide (Siebenga et al., 2009). Many noroviruses have been re-
ported such as Norwalk virus (Jiang et al., 1993), Hawaii virus (Lew
et al., 1994a), Snow Mountain virus (Lochridge and Hardy, 2003),
Desert Shield virus (Lew et al., 1994b), Southampton virus (Clarke and
Lambden, 1997) and Lordsdale virus (Lambden et al., 1993).
The norovirus genome consists of a single-stranded positive-sense
RNA molecule of 7.5–7.7 kb in length and contains three open reading
frames (ORFs) (Lambden et al., 1993), except for the murine norovirus
which has a fourth alternative ORF (McFadden et al., 2011). ORF1
encodes a 200 kDa non-structural polyprotein which is co- and post-
translationally cleaved into six or seven non-structural proteins by the
viral 3C-like protease (NS6). The seven products of this proteolysis are,
from N-terminus to C-terminus: p48 (NS1-2), an NTPase (NS3), a 3A-
like protein (p22, NS4), a viral genome-linked protein (VPg, NS5), the
3C-like protease (3CLpro, NS6) and an RNA-dependent RNA polymerase
(RdRp, NS7) (Blakeney et al., 2003). ORF2 and ORF3 encode the capsid
protein VP1 and the minor structural protein VP2, respectively.
The 3C-like protease (3CLpro) was named because of its similarity to
the picornavirus 3C protease. It is a cysteine protease which shows a
typical chymotrypsin-like fold containing two domains: a β-barrel do-
main and a β-sheet domain separated by a groove where the active site
is located (Bazan and Fletterick, 1988; Boniotti et al., 1994). The active
site is characterised by a catalytic dyad (Cys139-His30) (Someya et al.,
2002) or triad (Cys139-His30-Glu54) (Tiew et al., 2011) and shows a
strong preference for a –D/E-F/Y-X-L-Q-G-P- (X can be H, Q, or E) se-
quence corresponding to the subsites S5-S4-S3-S2-S1-S1′-S2′ (Tiew et al.,
2011). Studies have indicated that norovirus 3CL proteases have a
preferential order of processing the polyprotein, for example, the
Southampton virus 3CLpro has a preference for cleavage at LQ-GP and
LQ-GK, but it can also cleave at ME-GK, FE-AP and LE-GG (Hussey
et al., 2011). Although several norovirus 3CLpro structures have been
determined (Hussey et al., 2011; Nakamura et al., 2005; Zeitler et al.,
2006), the full structural basis of how these enzymes recognise these
different sites is still unknown. The key role of norovirus 3CLpro in the
processing of the polyprotein and the absence of homologues in the
human host make it an excellent target for antiviral drug discovery.
There is currently no clinically approved norovirus 3CLpro inhibitor
available but several compounds have been reported with strong in-
hibitory activity against 3CL proteases in vitro. These are usually pep-
tidyl or macrocyclic compounds mimicking the substrate sequence
whilst possessing a transition state analogue (Damalanka et al., 2017;
Kankanamalage et al., 2015; Mandadapu et al., 2012). Examples in-
clude peptidyl aldehydes and α-ketoamides which showed strong in-
hibition of norovirus 3CLpro, and the 3C or 3C-like proteases in pi-
cornaviruses and coronaviruses in cell-based assays (Kim et al., 2012).
The aldehydes and α-ketoamides act as warheads which form a re-
versible adduct with the catalytic residue Cys139 in the active site (Kim
et al., 2012). These compounds are named as latent transition state (TS)
inhibitors. TS mimics, such as α-hydroxyphosphonate, are converted to
the aldehyde form either with or without catalytic action of the enzyme
and form a tetrahedral adduct with the Cys139 residue
(Kankanamalage et al., 2015). Hussey et al. (2011) first reported the X-
ray structure of the Southampton norovirus 3CLpro (SV3CP) with an
inhibitor bound. This compound consisted of part of the most rapidly
cleaved substrate sequence (EFQLQ) with a Michael acceptor moiety
linked to the P1 residue Gln. This is attacked by Cys139 and a covalently
bound complex is formed. Interestingly, the His30 sidechain is pushed
away by the inhibitor, which disrupts the catalytic triad.
Screening by mass-spectrometry for covalent inhibitors of SV3CP has
been described by us previously (Resnick et al., 2019). In this work we
have crystallised the protease in its native form with an unperturbed
catalytic triad and have conducted crystal-based fragment screening of
844 compounds with the aim of discovering novel inhibitory functional
groups which have the potential to be developed as therapeutic agents,
either on their own or through chemical coupling. A total of 19 com-
pounds were found to bind to 3CLpro in the crystals and two of them were
located in the active site while another 5 were located at the enzyme’s
putative RNA-binding site. A further 10 compounds were found to bind in
the central cavity of this putative tetrameric form of the enzyme.
2. Methods
2.1. Crystallisation
Expression and purification of SV3CP was conducted using the
method described by Hussey et al., (2011). Screening for crystallisation
conditions for SV3CP was accomplished using the sitting-drop method
at 21 °C with the screening kits: Structure Screen 1 & 2, JCSG-plus,
PACT premier, MIDAS and Morpheus from Molecular Dimensions (Suf-
folk, UK). A TTP Labtech Mosquito crystal screening robot (TTP Lab-
tech, Hertfordshire, UK) was used to dispense 400 nl of the protein, at
concentrations of 5 mg/ml and 10 mg/ml, with 400 nl of the corre-
sponding well solution into each drop. High quality crystals were ob-
tained in 0.2 M ammonium citrate and 12% (v/v) PEG3350 after ap-
proximately one week, although crystals kept appearing over the next
2–3 months prior to screening.
2.2. Data collection, data processing and structure determination
Selected crystals were cryo-protected in 30% glycerol and mounted
in loops before flash-cooling. X-ray data were collected at beamline I04-
1 at Diamond Light Source (DLS, Didcot, England). Fine-sliced data
were collected as guided by the strategy suggested by the program
EDNA (Incardona et al., 2009). Data were processed automatically by
the program xia2 (Winter, 2010) at DLS, which revealed the space
group to be C2, as shown in Table 1. Further analysis using Phenix.xt-
riage (Zwart et al., 2005) suggested that the data were of good quality.
The solvent content of this crystal form was estimated to be 44.9%
using Matthews_coef (Kantardjieff and Rupp, 2003).
The structure was determined by use of the program Phaser MR
(McCoy et al., 2007) using the protein moiety of the published SV3CP-
MAPI complex (PDB ID: 2iph) as a search model. Several rounds of
manual rebuilding and correction were performed using Coot (Emsley
and Cowtan, 2004) followed by restrained refinement using Refmac5
(Murshudov et al., 2011) and Phenix.refine (Afonine et al., 2012). Since
the crystal diffracted to near atomic resolution, the temperature factors
were refined anisotropically. Structure validation was performed with
MolProbity (Chen et al., 2010). The statistics for data collection, data
processing and refinement are shown in Table 1.
2.3. In crystallo fragment screening
2.3.1. Crystal preparation
Crystals were prepared in Swissci 3-drop crystallisation plates
(Hampton Research, CA, USA) in 200 nl droplets containing 100 nl of
the protein (4 mg/ml) and 100 nl of well solution [0.2 M ammonium
citrate, 12% (v/v) PEG3350]. Since all of the fragments were dissolved
in 100% dimethyl sulfoxide (DMSO), crystal stability in this solvent was
first tested in the range (v/v) of 0%, 10%, 20%, 30% and 40%, and on
soaking time scales of 1 h, 3 h and overnight. In order to make the
experiment more efficient, the crystals were also tested with and
without additional cryo-protectant for data collection. It was found that
these crystals could survive in 40% DMSO for many hours and addi-
tional cryo-protection was not required.
2.3.2. Fragment soaking, crystal harvesting and data collection
The plates containing crystals were imaged using a Rock imager
system (Formulatrix, USA). All the crystals were then ranked using the
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Table 1
X-ray statistics for the native SV3CP structure and fragment complexes. Values
in parentheses are for the high resolution shell. For the minority of structures
where the overall fragment occupancy was either refined or is less than unity
due to proximity with a symmetry axis, the fractional occupancy is shown
following the mean fragment B-factor.
Fragment Native J01 J02 J03
PDB-ID 6t1q 6 t49 6t6w 6t2i
a (Å) 63.14 62.72 62.94 62.73
b (Å) 89.37 89.35 89.46 89.35
c (Å) 61.60 60.69 61.20 60.92
β (°) 96.50 96.57 96.89 96.95
Resolution (Å) 41.26–1.30
(1.33–1.30)
60.29–1.56
(1.60–1.56)
44.73–1.80
(1.85–1.80)
51.09–1.61
(1.65–1.61)
Completeness
(%)
99.9 (99.9) 99.8 (99.8) 98.6 (99.4) 99.8 (99.7)
Rmerge (%) 4.4 (139.6) 7.0 (78.0) 9.8 (66.8) 5.4 (75.6)
Rmeas (%) 4.8 (152.5) 8.3 (99.1) 11.7 (79.3) 6.5 (96.7)
CC½ (%) 100.0 (55.3) 99.8 (45.4) 99.4 (64.7) 99.8 (62.1)
Mean I/σ(I) 13.6 (1.1) 7.2 (1.3) 8.9 (1.8) 8.3 (1.1)
Multiplicity 6.6 (6.2) 3.2 (2.6) 3.3 (3.4) 3.1 (2.5)
N observed 544,844
(38403)
149,418
(9035)
102,005
(7693)
135,174
(8082)
N unique 83,130
(6151)
47,120
(3473)
30,724
(2263)
43,021
(3176)
R-factor 15.08 15.34 14.40 15.40
Free R-factor 20.07 22.10 24.43 23.78
Test set size 4243 2236 1496 2154
R.m.s.d. bond
lengths (Å)
0.015 0.013 0.011 0.013
R.m.s.d. bond
angles (°)
1.88 1.84 1.80 1.87
Mean protein B-
factor (Å2)
25.83 24.14 26.35 29.88
Mean fragment
B-factor
(Å2)
– 35.31 47.04, 0.86 25.55
Fragment J04 J05 J06 J07
PDB-ID 6t4e 6t4s 6tbp 6t71
a (Å) 62.91 62.90 62.74 63.14
b (Å) 89.56 90.02 89.21 89.39
c (Å) 61.37 60.97 61.08 61.37
β (°) 96.64 97.06 96.82 96.73
Resolution (Å) 25.62–1.66
(1.70–1.66)
60.51–2.02
(2.07–2.02)
60.64–1.56
(1.60–1.56)
60.95–1.52
(1.56–1.52)
Completeness
(%)
97.1 (95.9) 99.4 (98.9) 96.1 (82.9) 99.8 (99.6)
Rmerge (%) 6.7 (84.8) 14.9 (113.0) 5.1 (56.1) 4.7 (53.6)
Rmeas (%) 7.9 (105.3) 17.8 (134.8) 6.1 (71.1) 5.6 (67.6)
CC½ (%) 99.8 (42.5) 98.6 (50.9) 99.8 (67.4) 99.8 (78.8)
Mean I/σ(I) 12.4 (1.3) 5.3 (1.6) 9.0 (1.1) 9.6 (1.5)
Multiplicity 3.3 (2.9) 3.4 (3.3) 3.2 (2.6) 3.1 (2.5)
N observed 128,715
(7931)
73,672
(5243)
143,761
(7511)
162,852
(9643)
N unique 38,595
(2774)
21,956
(1583)
45,526
(2915)
51,832
(3801)
R-factor 13.71 21.36 13.74 13.85
Free R-factor 21.13 29.99 20.06 19.92
Test set size 1888 1052 2157 2517
R.m.s.d. bond
lengths (Å)
0.012 0.009 0.012 0.012
R.m.s.d. bond
angles (°)
1.89 1.75 1.76 1.83
Mean protein B-
factor (Å2)
29.98 32.85 28.89 28.22
Mean fragment
B-factor
(Å2)
48.52 52.58 41.21 37.40
Fragment J08 J09 J10 J11
PDB-ID 6t2x 6t5d 6t5r 6tc1
a (Å) 62.89 62.80 62.74 63.02
b (Å) 89.36 89.26 89.32 89.72
c (Å) 61.44 61.49 61.38 61.53
Table 1 (continued)
Fragment J08 J09 J10 J11
β (°) 96.73 96.67 96.80 96.67
Resolution (Å) 20.70–1.54
(1.58–1.54)
61.07–1.42
(1.46–1.42)
41.18–1.78
(1.83–1.78)
24.51–1.67
(1.71–1.67)
Completeness
(%)
95.6 (85.5) 96.4 (86.8) 98.2 (99.5) 97.0 (95.7)
Rmerge (%) 5.0 (88.9) 3.4 (67.2) 9.2 (81.2) 4.6 (79.6)
Rmeas (%) 6.0 (112.6) 4.2 (90.8) 11.1 (97.3) 5.5 (99.5)
CC½ (%) 99.7 (50.4) 99.9 (50.2) 96.9 (59.3) 99.9 (46.9)
Mean I/σ(I) 12.7 (1.1) 15.0 (1.2) 11.7 (1.4) 15.2 (1.3)
Multiplicity 3.2 (2.6) 2.9 (2.1) 3.3 (3.2) 3.2 (2.8)
N observed 153,253
(8097)
179,818
(8428)
104,626
(7712)
123,219
(7726)
N unique 47,528
(3127)
60,967
(4032)
31,627
(2378)
38,160
(2789)
R-factor 13.72 13.12 14.13 12.83
Free R-factor 19.75 19.47 22.75 20.99
Test set size 2340 3026 1537 1849
R.m.s.d. bond
lengths (Å)
0.014 0.015 0.011 0.012
R.m.s.d. bond
angles (°)
1.91 2.04 1.82 1.81
Mean protein B-
factor (Å2)
30.12 26.47 30.51 33.85
Mean fragment
B-factor
(Å2)
34.85 26.47, 0.50 44.42, 0.50 40.59
Fragment J12 J13 J14 J15
PDB-ID 6tbo 6taw 6tgl 6t8t
a (Å) 62.74 62.93 62.88 63.09
b (Å) 89.46 89.03 89.20 89.51
c (Å) 61.15 61.35 61.18 61.07
β (°) 97.45 97.27 97.08 97.55
Resolution (Å) 31.11–2.07
(2.12–2.07)
51.11–1.41
(1.45–1.41)
25.10–1.99
(2.04–1.99)
25.07–1.68
(1.72–1.68)
Completeness
(%)
98.1 (99.2) 96.0 (87.6) 98.9 (98.9) 99.4 (99.7)
Rmerge (%) 17.8 (71.6) 4.1 (53.0) 10.3 (44.8) 6.4 (80.6)
Rmeas (%) 21.4 (85.9) 4.9 (68.8) 12.3 (54.0) 7.6 (96.7)
CC½ (%) 97.8 (61.5) 99.9 (64.7) 99.3 (66.8) 99.8 (53.4)
Mean I/σ(I) 5.1 (1.6) 10.4 (1.1) 9.3 (2.8) 12.0 (1.5)
Multiplicity 3.2 (3.3) 3.0 (2.2) 3.3 (3.1) 3.4 (3.2)
N observed 65,116
(5021)
187,385
(9225)
74,353
(5270)
128,009
(9019)
N unique 20,052
(1524)
61,836
(4148)
22,739
(1682)
38,064
(2797)
R-factor 20.42 12.83 16.98 12.21
Free R-factor 28.99 17.79 23.71 19.39
Test set size 981 3151 1113 1911
R.m.s.d. bond
lengths (Å)
0.008 0.014 0.008 0.013
R.m.s.d. bond
angles (°)
1.60 1.89 1.54 1.78
Mean protein B-
factor (Å2)
35.81 24.37 29.57 30.70
Mean fragment
B-factor
(Å2)
37.03 18.97 49.91 39.18
Fragment J16 J17 J18 J19
PDB-ID 6t82 6tcf 6tal 6t8r
a (Å) 63.01 63.20 62.69 62.96
b (Å) 89.34 89.49 90.02 89.78
c (Å) 61.43 61.47 60.79 60.92
β (°) 97.08 96.93 96.23 96.42
Resolution (Å) 60.96–1.46
(1.50–1.46)
51.37–1.79
(1.84–1.79)
51.24–1.51
(1.55–1.51)
60.54–1.88
(1.93–1.88)
Completeness
(%)
96.4 (86.0) 99.8 (99.7) 99.3 (98.4) 99.8 (99.8)
Rmerge (%) 5.0 (62.7) 8.8 (55.1) 5.8 (68.0) 9.5 (66.5)
Rmeas (%) 6.0 (80.0) 10.5 (65.3) 6.9 (86.9) 11.3 (79.6)
CC½ (%) 99.7 (73.9) 98.2 (80.4) 99.9 (64.1) 99.4 (68.4)
Mean I/σ(I) 8.8 (1.2) 6.5 (1.6) 9.3 (1.3) 5.9 (1.6)
Multiplicity 3.1 (2.4) 3.3 (3.4) 3.1 (2.5) 3.3 (3.3)
(continued on next page)
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program TeXRank (Ng et al., 2014) and positional coordinates for the
injection of the fragments were manually defined in the drop. Each
fragment from the DSLP library (776 fragments) (Cox et al., 2016) and,
due to time constraints, a subset of the Maybridge Ro3 core set (first 68
fragments) (Fisher Scientific UK Ltd, Loughborough, UK) was acousti-
cally dispensed to the corresponding target position in droplets of 2.5 nl
volume using a Labcyte Echo 550 liquid handler (Labcyte Inc, CA, USA)
which gave an estimated final fragment concentration of 200 mM
(Collins et al., 2017). Fragment soaking was conducted in batches to
give an average soaking time of approximately 2.5 h prior to crystal
mounting. Crystal harvesting was aided by the use of a crystallisation
plate shifter (Oxford Lab Technologies, Oxford, UK). All the crystals
were mounted in loops of about the same size as the crystals or slightly
smaller to allow for automated, unattended data collection in which the
X-ray beam was aimed at the centre of each loop. A total of 180° of data
were collected for each crystal, taking approximately 60 s per crystal
using DLS beamline I04-1.
2.3.3. Fragment data processing, analysis and hit identification
The data produced were managed using XChemExplorer (Krojer
et al., 2017) which gathered ligand information and data processing
results and launched different software pipelines, such as DIMPLE
(Wojdyr et al., 2013) for generating difference maps and PanDDA
(Pearce et al., 2016) for further analysis and hit identification. PanDDA
uses an average of several ground-state crystal structures to calculate a
background density correction which reveals better electron density for
weakly bound fragments. All the hits were checked visually by using the
program Pandda.inspect in the PanDDA suite (Pearce et al., 2016). The
hits were further refined using Refmac5 (Murshudov et al., 2011) fol-
lowed by inspection using Coot (Emsley and Cowtan, 2004) for several
rounds (Table 1). In most cases anisotropic B-factor refinement was
undertaken and the fragment occupancy was fixed. Confirmatory omit
maps for the ligands were generated using the program Composite omit
map (Terwilliger et al., 2008) in the PHENIX program suite (Adams
et al., 2010). Interactions between ligands and SV3CP were analysed
using LigPlot+ (Wallace et al., 1995). Figures were prepared using
programs MarvinSketch (ChemAxon, 2013), PyMOL (The PyMOL Mo-
lecular Graphic System, Schrödinger, LLC) and CueMol (Molecular Vi-
sualization Framework http://www.cuemol.org).
2.4. Activity assay
The protease (0.5 mg/ml final concentration) in a buffer containing
100 mM Tris, pH 8.5, and 5 mM β-mercaptoethanol was mixed with the
fragment (dissolved in DMSO at concentrations of 0.027, 0.135, 0.27,
0.405 and 0.54 mM) for 20 min at RT. The solution was then mixed
with the chromogenic substrate (Ac-EFQLQ-para-nitroaniline; Peptide
Protein Research Ltd, Southampton, UK), which was dissolved in DMSO
to give final concentrations of 0.4, 0.9, 1.4, 1.9, 2.5 and 3.0 mM, in a
1:1 ratio and the absorbance at 405 nm was measured at 20 s intervals
over a 3 min period, using a Nanodrop ND1000 spectrophotometer. The
Ki values were determined using GraphPad Prism (www.graphpad.com).
3. Results
3.1. Structure of native SV3CP
The structure of native SV3CP has been determined for the first time
at the near-atomic resolution of 1.3 Å resolution (Fig. 1a) revealing a
crystallographic tetramer (Fig. 1b). The monomers consist of an N-
terminal and a C-terminal domain with the active site cleft located in
between. As found in other noroviral 3CLpro structures, the N-terminal
domain contains an α-helix and a twisted 7-stranded antiparallel β-
sheet forming an incomplete β-barrel (Anand et al., 2002; Birtley et al.,
2005; Mosimann et al., 1997). The C-terminal domain is made up of 6 β-
strands forming an antiparallel β-barrel and contains the catalytic cy-
steine residue (Cys139) which makes a catalytic triad with two residues
from the N-terminal domain (His30 and Glu54; Fig. 1a). Interestingly,
the β-hairpin formed by β9 and β10, which is involved in binding the N-
terminal side of the substrate peptide, adopts an appreciably different
conformation from that observed in an earlier inhibitor-complexed
structure (Fig. 1c; Hussey et al., 2011). It is now clear that the backbone
of this β-hairpin moves by over 7 Å to open up the active site cleft for
substrate binding and movements of some of the side chain atoms ex-
ceed of 12 Å. Indeed, in the native enzyme, residues Met107 to Gln110
occupy very approximately the same positions as the P5 - P3 residues of
the bound substrate analogue and the sidechain of Arg112 occupies the
position of the P2 sidechain (Fig. 1d). In addition to the movement of β9
and β10, the β-hairpin formed by strands β11 and β12 also moves to
some extent. These effects open up the active site, suggesting that a
fairly marked conformational change occurs upon binding of substrate.
The Michael acceptor inhibitor also pushes His30 away from the other
members of the catalytic triad (Cys139 and Glu54, Fig. 1c).
The SV3CP enzyme has approximately 90% sequence identity with
other GI noroviral 3C proteases and an identity of the order of 68% with
the enzyme from the GII genotype. SV3CP has approximately 58%
identity with the mouse norovirus enzyme. The monomer structures of
these enzymes superpose with SV3CP with a Cα RMSD of typically 1.0 –
1.2 Å for virtually all of the amino acids in the chains. The structures
differ most noticeably in the hairpin linking strands β9 and β10 which is
close to the active site.
In line with other noroviral 3C proteases which have been analysed
by gel-filtration, it is highly likely that SV3CP forms dimers in solution
or, at least, exists in a monomer – dimer equilibrium (Chang et al.,
2012; Leen et al., 2012; Zeitler et al., 2006). Accordingly, a dimer is
observed in the crystallographic asymmetric unit of SV3CP (Fig. 2,
chains A and B). However, analysis with the PDBePisa website (Krissinel
and Henrick, 2007) suggested a tetrameric form (Fig. 1b) might also be
stable in solution. The interface area between the chains of the crys-
tallographically observed dimers (formed by chains A and B) is
883.0 Å2. However, a neighbouring dimer in the crystal structure forms
an interface of comparable buried surface area (692.3 Å2) between
chains labelled A and D chains and likewise for chains labelled the B
and C. This result indicates that higher order oligomers may possibly be
formed by SV3CP dimers, such as the putative tetramer shown in
Fig. 1b. Intriguingly, a number of other human GI and GII noroviral
protease structures (Nakamura et al., 2005, RCSB ID: 1wqs; Muzzarelli
et al., 2019, RCSB ID: 6b6i; Viskovska et al., 2019, RCSB ID: 6nir) form
essentially the same tetrameric assembly in the crystals, as shown in
Supplementary Fig. 1. The majority of the amino acids forming the
tetramer contacts (Glu79, Met101, Ala103, Ala105, Ser106, Met107,
Arg108, Met120, Leu121, Leu122, Thr161, Ser163, Asn165, Thr166)
are either invariant or conservatively substituted. The same tetramer is
also observed in mouse norovirus protease (Fernandes et al., 2015,
Table 1 (continued)
Fragment J16 J17 J18 J19
N observed 175,458
(8933)
106,031
(8062)
163,299
(9646)
89,757
(6547)
N unique 56,264
(3720)
31,951
(2374)
52,139
(3788)
27,348
(2005)
R-factor 13.75 14.52 14.35 13.70
Free R-factor 19.67 23.29 21.66 24.30
Test set size 2826 1559 2622 1339
R.m.s.d. bond
lengths (Å)
0.015 0.011 0.013 0.010
R.m.s.d. bond
angles (°)
1.90 1.70 1.80 1.65
Mean protein B-
factor (Å2)
26.59 28.41 20.74 34.66
Mean fragment
B-factor
(Å2)
26.53, 0.50 40.47 23.78 56.50
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Fig. 1. (a) The overall structure of SV3CP with the β-strands labelled. The protein is composed of an N-terminal domain (red) containing a twisted 7-stranded
antiparallel β-sheet and a C-terminal domain (green) consisting of a 6-stranded β-barrel. The catalytic triad of Cys139, His30 and Glu54 is shown in stick re-
presentation. (b) The putative tetrameric form of SV3CP. The asymmetric unit is composed of a dimer formed by chains denoted A and B. Crystallographic symmetry
generates another identical dimer formed by chains denoted C and D. Both the AB and CD dimers have significant buried surface area suggesting that the dimer is
physiologically significant. However another stable interface is formed between chains A and D and between chains B and C, resulting a tetrameric ensemble which
may also have physiological significance. The domains of chain A are coloured and oriented the same as in (a) whereas chains B, C and D are coloured yellow, cyan
and ochre. (c) Superimposition of the protein moieties of ligand-free SV3CP (green) and the polypeptide inhibitor-bound structure (Hussey et al., 2011; RCSB ID:
2iph) (pale brown). The ligand-free SV3CP structure has a shorter C-terminal end labelled C1 whereas this part of the complex with the substrate-analogue inhibitor
is labelled C2. The red asterisk indicates the β-hairpin (between strands β9 and β10) which undergoes substantial movement upon binding the inhibitor. (d) A close-
up of the superposition showing the polypeptide Michael acceptor inhibitor (MAPI) coloured cyan and a number of residues in the β-hairpin, including Arg112 which
moves drastically upon binding the inhibitor. (e) A surface representation of ligand-free SV3CP demonstrating the relatively closed state of the active site cleft
(arrowed A). (f) A surface representation of the complex with MAPI in which the active site has opened appreciably to accommodate the polypeptide moiety of the
inhibitor.
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RCSB ID: 4x2v) which has lower sequence identity with SV3CP (~58%)
than do the other human GI or GII proteases (~91% and 68%, re-
spectively). These findings, along with the ability of the tetramer cavity
to bind small molecule fragments (see later), suggest that this tetra-
meric form may have functional significance for 3CLpro. Indeed, in the
structure of the Minerva virus enzyme (RCSB ID: 6b6i) the tetrameric
assembly allows the C-terminal ends of two monomers (equivalent to B
and D) to extend into the active sites of adjacent monomers (C and A,
respectively) across the dimer-dimer interface (Muzzarelli et al., 2019).
Similar tail-interdigitating effects are observed in the structures of the
protease from Houston virus (RCSB ID: 6nir; Viskovska et al., 2019) and
mouse norovirus (RCSB ID: 4x2v; Fernandes et al., 2015). Given that
localised replication centres are known to form within norovirus-in-
fected cells (e.g. Thorne and Goodfellow, 2014), a high local con-
centration of 3CLpro may allow the enzyme to tetramerise.
In the native SV3CP structure, no electron density is visible for the
last 8 residues (ASEGETTL) at the C-terminal end of the protein. Since
these residues are well-defined in the complex with a substrate ana-
logue (Hussey et al., 2011), their absence in the native structure might
be due to autolysis during storage or crystallisation of the uninhibited
protease. In this region of the structure, there is a minor consensus
sequence for SV3CP cleavage with the following amino acids VQ-AS
corresponding to the P2-P1-P1′-P2′ positions (Hussey et al., 2011;
Kankanamalage et al., 2015) suggesting that slow autolysis prior to
crystal growth is possible. Mass spectrometric analysis of the purified
protein yielded a molecular mass of 19,290 Da (Supplementary Fig. 2)
confirming that the protease was indeed fully intact at the time of
crystallisation. Therefore another possibility is that this region of the
molecule is simply disordered in the new crystal form. However, it is
not clear why this should be since this region of both monomers is not
involved in crystal contacts in either crystal form.
3.2. Crystal-based fragment screening
Most crystals used in the non-covalent fragment screening experi-
ment diffracted to resolutions ranging from 1.5 to 1.8 Å with good
Fig. 2. Binding sites of the fragment screening hits. All the ligands bind in five
sites labelled as A – E which are shown on a surface representation of the dimer.
Site A coincides with the active site of the protease and site B is a putative RNA
binding site. Site C coincides with the centre of the tetramer.
Fig. 3. Molecular structures of the fragment screening hits.
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crystallographic statistics (Table 1). Fragment J12 is the worst in terms
of resolution, diffracting to approximately 2.1 Å, although the electron
density is still of good quality. Screening with the DSPL library and part
of the Maybridge Ro3 library identified 19 ligands in total which bind
in five different sites, as illustrated in Fig. 2. The majority of fragments
have mean B-factors which are comparable with those of the protein
moieties (Table 1). In only one case (J02) was the occupancy of the
fragment refined, although for several others it was set to 0.5 due to the
fragments residing on a 2-fold axis.
Site A, the protease active site, is a long groove containing the
catalytic Cys139 residue. Two fragments (J01 and J02) were found to
bind here, each on different sides of the catalytic cysteine (Fig. 2). Five
hits (J03-J07) were found to bind in the putative RNA binding site (site
B) including one (J07) which also binds in another site, site C. Site C
lies in a pocket between chains A and B and the symmetry related
chains A’ and B’, with 11 hits being identified (J07-J17) here. Two
other fragments were found at additional sites: D (J18) and E (J19).
Molecular structures of the ligands J01-J19 are given in Fig. 3.
3.2.1. Active site-binding fragments (site A)
Two non-covalently bound fragments were identified in the active
site of the protease named as J01 and J02, as indicated by their omit
maps (Fig. 4a and c). J01 binds in the S1 subsite where its carboxyl
group is oriented towards S2 and S3. J01 forms several direct hydrogen
bonds with the side chains of Gln110 and Arg112 and makes some
additional hydrogen bonds mediated by a water molecule (Fig. 4a and
b). These residues are at the tip of the functionally important β-hairpin
(connecting strands β9 and β10) that is involved in substrate recogni-
tion and moves substantially upon binding of polypeptide substrate
analogues (Fig. 1). However, in the presence of J01, the β-hairpin
adopts the same conformation as the ligand-free SV3CP, suggesting that
binding of this fragment does not alter its conformation. Since the
carboxyl group of J01 appears to hold the β-hairpin loop (residues 109
to 112) in the closed conformation, this must help to prevent the en-
zyme from adopting the 'open' conformation that can accommodate the
substrate. The ligand –NH group (N1) is also within hydrogen bonding
distance of the main chain carbonyl group of Thr134. The benzoic acid
moiety of J01 makes many hydrophobic interactions with the active
site residues including Pro136, Cys139 and Ala160. In contrast, the 5-
methyl-2-thienyl group forms fewer contacts with the enzyme than the
aromatic group since it points away from the active site towards a large
solvent channel.
J02 resides on the other side of the long active site, where it oc-
cupies the S2 subsite without forming any hydrogen bonds (Fig. 4c and
d). Instead, the phenyl ring is sandwiched between the side chains of
His30 of the catalytic triad and Arg112 from the β-hairpin loop by π - π
Fig. 4. The two active site binding fragments (site A). J01 (magenta) and J02 (green) are shown in (a) and (c) with the omit maps (contoured at 1.0 RMSD) coloured
blue. The interactions between SV3CP and these fragments are shown in (b) and (d), respectively. Hydrogen bonds are indicated by dashed lines in cyan with the
corresponding donor–acceptor atom distances shown in Å. Hydrophobic interactions are indicated by red eyebrow-like icons.
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stacking and cation - π interactions. Interestingly, the guanidinium
group of Arg112 has moved from its position in the other fragment
complex to accommodate J02. Several hydrophobic interactions are
formed between this fragment and Glu54 from the catalytic triad and
Val114, and a number of contacts are made with a symmetry-related
molecule.
In kinetic assays both J01 and J02 showed inhibitory activity
against SV3CP with Ki values of 0.37 mM and 0.34 mM, respectively.
These values are typical of initial hits in crystallographic fragment-
screening studies targetting catalytic- or allosteric-sites of enzymes
(Bauman et al., 2013; Delbert et al., 2018; Zhang et al., 2019) sug-
gesting that the binding modes we observe in 3CLpro are highly re-
levant. Since J01 and J02 bind in the active site cleft and maintain the
closed conformation of the hairpin, they are good candidates for de-
veloping further inhibitors and linking them into a new compound
could also improve the bioactivity. A superposition of their binding
modes on that of the covalently bound Michael acceptor inhibitor
(Fig. 5) demonstrates how these two fragments occupy the S1 and S2
subsites, respectively. J02 does not overlap with the P2 residue of the
polypeptide inhibitor as well as J01 and the P1 residue do, since it
appears to lie somewhere between the spatially adjacent S2 and S1′
subsites.
3.2.2. Fragments binding at the putative RNA binding site (site B)
In addition to the protease activity, studies on viral 3C proteases
suggested that they or their larger precursors can bind specifically to
the 5′-terminal nucleotides of the viral RNA (Leong et al., 1993; Nayak
et al., 2006). The interaction occurs only on the plus strand which forms
a ribonucleoprotein (RNP) complex that is necessary for the initiation of
the plus strand synthesis (Andino et al., 1990). It has been shown that
Fig. 5. A superposition of the two active-site binding fragment structures on a
covalently bound substrate analogue inhibitor. The complexes with J01 and J02
are coloured magenta and green, respectively, while the polypeptide Michael
acceptor inhibitor structure (RCSB ID: 2iph; Hussey et al., 2011) is shown in
cyan. The C-terminal end of ligand-free SV3CP is labelled C1 and the corre-
sponding part of the polypeptide inhibitor complex is labelled C2. The β-hairpin
loop connecting strands β9 and β10 moves significantly from its position in the
native structure (which is very close to its position in the J01 and J02 com-
plexes) upon binding the polypeptide inhibitor.
Fig. 6. Interactions between the putative RNA binding site (site B) of the pro-
tease and fragments J03-J07. These are shown in 3D with the omit electron
density contoured at 1.0 RMSD as (a, c, e, g, i) and in 2D with interacting
residues shown in (b, d, f, h, j), respectively. Hydrogen bonds are indicated by
dashed lines in cyan and hydrophobic interactions are indicated by red eye-
brow-like icons. Protein chain identifiers are indicated by the letters A and B in
brackets and those with a prime are from symmetry-related chains.
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human noroviral RNA non-competitively inhibits the protease activity
with an IC50 of in the µM range (Viswanathan et al., 2013). The RNA
binding site has been studied by mutagenesis in other homologous 3C
proteases, in which a key arginine residue was identified in the con-
served sequence, KF/VRDI (F/V represents F or V) (Bergmann et al.,
1997; Leong et al., 1993; Nayak et al., 2006). Structural comparison of
SV3CP with HRV 3CLpro (PDB ID: 5fx5; Kawatkar et al., 2016) and
FMDV 3CLpro (PDB ID: 2j92; Nayak et al., 2006) identified Arg65 as the
equivalent residue in SV3CP, which is within a KIRPDL sequence that
has similarity with the consensus. The R and D residues in this sequence
interact by a salt-bridge that forms one side of the putative RNA binding
site of SV3CP (site B) which is shown in Fig. 2 and, as for the FMDV and
HRV proteases, it is a shallow groove. In addition, these sites are on the
surface of the SV3CP tetramer and form deep channels with the
neighbouring symmetry-related molecules in HRV, FMDV and South-
ampton virus 3CLpro. Inhibitors binding in the RNA binding site have
the potential to inhibit noroviral replication and are therefore of in-
terest as a separate class of drug.
Fragments J03-J06 were found to reside at this site and their contact
residues are shown in Fig. 6. All the fragments form hydrophobic
contacts with Arg65 and other residues in the KIRPDL sequence. While
J03 (Fig. 6a and b) and J06 (Fig. 6g and h) are mainly involved in
hydrophobic interactions, J04 (Fig. 6c and d) and J05 (Fig. 6e and f)
also form many hydrogen bonds with the neighbouring residues, po-
tentially making them stronger binders. The carbonyl group (O1) of J04
is involved in three hydrogen bonds formed, directly or mediated by a
water molecule, with Thr10, Lys11 and Ser91 (although the latter re-
sidue is from a symmetry related molecule). The N1 atom forms two
hydrogen bonds with Ser7 and Pro3 (also from the symmetry mate)
with the participation of a water molecule. A hydrogen bond is also
seen between the fluorine substituent in the indole ring of J04 and the
NE1 atom on the side chain of Trp19. This residue is one of a number of
quite solvent-exposed aromatic residues including phenylalanines 12,
25, 39 and 40 which form the putative RNA-binding site. J05 also forms
water-mediated hydrogen bonds with Ser91 from the symmetry related
molecule. Unlike the active site fragments which bind in different
subsites of the substrate-binding channel, these four fragments bind in
approximately the same position with their aromatic 'heads' over-
lapping to a large degree but their aliphatic 'tails' pointing away in
different directions. Since binding of viral RNA inhibits the protease
activity (Viswanathan et al., 2013), ligands binding at this site have the
potential both to interfere both with RNA binding and with the protease
activity. However, since this site is of the order of 20 Å from the cat-
alytic centre the mechanism of protease inhibition is currently difficult
to explain. Fragment J07 was found to bind in both the putative RNA
binding site (B, Fig. 6i and j) and site C (Fig. 7a and b) in the centre of
the putative tetramer.
3.2.3. Fragments binding in the tetramer cavity (site C)
The finding that the native crystals of the enzyme are formed by a
tetrameric assembly of monomers is suggestive of a physiological role
for the tetramer. We were also intrigued to find that the majority of the
fragments binding to the protease (J07 - J17, Fig. 7) were located in a
cavity at the centre of the putative tetramer, site C. The site is char-
acterised by the convergence of two-fold symmetry axes, both crystal-
lographic and non-crystallographic, since the NCS two-fold relating the
monomers in each dimer and the crystallographic two-fold relating
both dimers in the tetramer meet at this point. The binding site is
formed by four copies of the hydrophobic amino acids Leu122 and
Val82 as well as Arg100 which are provided by all chains of the
Fig. 7. Interactions between SV3CP and fragments J07-J17 which bind in site C
at the centre of the putative tetramer. These are shown in 3D with the omit
electron density contoured at 1.0 RMSD as (a, c, e, g, i, k, m, o, q, s, u) and in 2D
with interacting residues shown in (b, d, f, h, j, l, n, p, r, t, v), respectively.
Hydrogen bonds are indicated by dashed lines in cyan and hydrophobic inter-
actions are indicated by red eyebrow-like icons. Protein chain identifiers are
indicated by the letters A and B in brackets and those with a prime are from
symmetry-related chains.
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tetramer. These residues have a high level of sequence conservation.
The sidechain of the arginine tends to form extensive stacking inter-
actions with the aromatic moieties of the ligand. Since this site is
formed at the convergence of 2-fold axes, two copies of each ligand are
present at this site and sometimes the two symmetry-related copies of
the fragment interact extensively with each other. Since the same tet-
rameric assembly is observed in other GI and GII norovirus proteases,
this binding site may be a conserved feature of these enzymes. Given its
ability to bind so many heteroaromatic fragments and the diverse
functions which noroviral proteins and their precursors are known to
have (e.g. Emmott et al., 2019), it is tempting to speculate that the
tetramer cleft has a physiological role, perhaps even as a secondary
substrate- or RNA-binding site.
3.2.4. Other fragment binding sites (D and E)
Two of the fragments (J18 and J19, Fig. 8) were found to bind at
unrelated sites involving crystal contacts which are probably not of
physiological significance. Site D lies close to Lys11, Lys88 and Glu93
whereas site E lies between Arg59 and the C-terminal end of the en-
zyme. The amide bond within J18 has apparently been cleaved and the
resulting fragments, trifluoroacetic acid and 2-ethyl-1,3,4-thiadiazole,
bind at sites C and D, respectively. Interestingly, it appears that the
amide bond in J11 has also been cleaved and the resulting 2-ethyl-
1,3,4-thiadiazole binds instead at site C. A check on the stock solution
of this compound was made mass spectrometry and this yielded a main
mass of 130 Da, which is within a dalton of the predicted molecular
mass of the observed fragment. It is possible that the electron with-
drawing groups on the amino terminal side of the amide bonds of these
two compounds may render them unstable in water.
4. Discussion
The X-ray structure of the Southampton virus 3CLpro has been de-
termined at 1.3 Å resolution in a crystal form that has allowed frag-
ment-screening for novel inhibitors to be undertaken at similar re-
solutions. Two fragments were found to bind in the active site cleft of
the protease. J01 and J02 bind in different subsites of the long active
site (see Fig. 5) but both of them interact with the functionally im-
portant β-hairpin linking strands β9 and β10. J01 occupies S1 and forms
hydrophobic interactions with catalytic Cys139 while J02 occupies S2
and forms hydrophobic and π-π interactions with Glu54 and His30,
which are also from the catalytic triad. Both J01 and J02 could po-
tentially be developed into more potent norovirus protease inhibitors,
however, a better ligand might ultimately be obtained by coupling them
together, given that the distance between the closest two atoms is
slightly less than 3.8 Å.
Some of the remaining fragments were found to interact with the
protease at its putative RNA-binding site. Whilst these compounds are
likely to have less effect on the protease activity than J01 and J02,
which bind in the active site, RNA binding to the enzyme has been
shown to cause non-competitive inhibition of the protease
(Viswanathan et al., 2013). Other fragments were found to bind at an
additional site which is buried deeply in the centre of the crystal-
lographic tetramer. The fact that a C193A mutant of the Minerva virus
protease forms the same tetramer in the crystal with the C-terminus of
one subunit occupying the active site cleft of another monomer
(Muzzarelli et al., 2019), suggests that this assembly may also be in-
volved in proteolytic maturation of noroviruses. Hence, compounds
that have the potential to interfere with formation of the tetramer or
affect its stability may impact on noroviral replication and therefore
deserve to be screened for in vivo activity, e.g. against mouse norvirus,
which can be cultured, or in a suitable replicon assay. If such studies
were to be successful, the highly symmetric nature of the binding site is
something that could, in principle, be exploited in drug design.
Given the recent COVID-19 pandemic, it is potentially useful to
compare our results on SV3CP with the 3CLpro of coronavirus (e.g. Yang
et al., 2013). The two enzymes have quite low sequence identity of
approximately 12% within the common protease moieties and super-
impose with an RMSD of 2.4 Å for 126 structurally aligned residues.
Fig. 7. (continued)
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The coronavirus protease is considerably larger (303 residues) than
SV3CP due to the presence of a C-terminal domain which is involved in
dimerisation. Although topologically similar, the protease moieties of
both structures differ very substantially in the loop regions connecting
the core β-strands. In spite of these differences, coronavirus protease
also has specificity for Gln at the P1 position of substrate. In very recent
fragment screening of the SARS-CoV-2 protease, 23 active site hits were
obtained which span the S3 to S1′ subsites of the enzyme, thus providing
Fig. 8. Interactions made by fragments J18 and J19. The amide bond within J18 has apparently been cleaved and the resulting fragments, 2-ethyl-1,3,4-thiadiazole
and trifluoroacetic acid, bind at sites D (a, b) and C (c, d), respectively. J19 binds at site E (e, f). These are shown in 3D with the omit electron density contoured at 1.0
RMSD. Hydrogen bonds are indicated by dashed lines in cyan and hydrophobic interactions are indicated by red eyebrow-like icons. Protein chain identifiers are
indicated by the letters A and B in brackets and those with a prime are from symmetry-related chains.
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somewhat better coverage of the active site cleft than we have achieved
with SV3CP (Douangamath et al., 2020). Other SARS-CoV-2 protease
inhibitor structures have also been reported in recent months (Dai et al.,
2020; Jin et al., 2020a,b; Zhang et al., 2020). This resurgence of interest
in rational 3CLpro drug design is likely to have combined benefits for
what are currently intractable and severe viral infections. These studies
provide a rational basis on which compounds with improved potency
can be designed by medicinal chemists.
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